Evidence map›Paper›PMID 38512581›Full record

ArticleGeroScience2024

Anti-cytomegalovirus antibody levels stratify human immune profiles across the lifespan.

Makiko Watanabe, Lisa Davidson, Patricia Smith, Peter F Castellucio, Mladen Jergovic, Jennifer L Uhrlaub, Megan J Smithey, Lori E Fantry, Brett Dechambre, Rachel C Wilson and 6 more

Open access · greenAbstract read
In one paragraph

Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cytomegalovirus and Aging-How Can the Field Move Forward?The Journal of infectious diseases · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Case Report: Pulmonary mixed infection byFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Makiko WatanabeDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Lisa DavidsonDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Patricia SmithDivision of Pulmonary Medicine, Department of Medicine, Indiana University College of Medicine, Bloomington, IN, USA.
Peter F CastellucioDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.
Mladen JergovicDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Jennifer L UhrlaubDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Megan J SmitheyDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Lori E FantryDivision of Infectious Diseases, Department of Medicine, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Brett DechambreDivision of Infectious Diseases, Department of Medicine, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Rachel C WilsonDivision of Pulmonary Medicine, Department of Medicine, Indiana University College of Medicine, Bloomington, IN, USA.
Kenneth C KnoxDepartment of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
Jie RenDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.
Raymond P StoweMicrogen Laboratories, La Marque, TX, USA.
George WeinstockJackson Laboratories, Bar Harbor, ME, USA.
Homer TwiggDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.
Janko Ž NikolichDepartment of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA. nikolich@arizona.edu.ORCID 0000-0001-5830-5323
University of Arizona · USIndiana University School of MedicineIndiana University Bloomington · USArizona Department of Health Services · USJackson Laboratory · USMicrogen (United States) · US

Funding

T Cell Homeostasis and Function in Immune SenescenceR37AG020719 · NIA · UNIVERSITY OF ARIZONA · PI JANKO Z. NIKOLICH · 2018 to 2026
$4.2M
Viral burden and systemic inflammation as biomarkers for chronic disease and frailty in agingU01AG060900 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI NIKOLICH, JANKO Z., TWIGG, HOMER L · 2018 to 2022
$3.5M
T Cell Homeostasis and Function in Immune SenescenceR01AG020719 · NIA · UNIVERSITY OF ARIZONA · PI NIKOLICH, JANKO Z. · 2001 to 2012
$3.1M
Disparities in Immune Fitness in HIV+ Subjects with AgingR21AG054317 · NIA · UNIVERSITY OF ARIZONA · PI NIKOLICH, JANKO Z. · 2016 to 2017
$410k
NIA NIH HHS R01 AG020719NIA NIH HHS R21 AG054317NIA NIH HHS R37 AG020719NIA NIH HHS U01 AG060900USPHS AG020719USPHS AG054317USPHS AG060900
6 · The paper itself

Abstract

Human cytomegalovirus (hCMV) is a ubiquitous latent persistent herpesvirus infecting 60-90% of the population worldwide. hCMV carriage in immunocompetent people is asymptomatic; thus, hCMV can be considered a component of normative aging. However, hCMV powerfully modulates many features of the immune, and likely other, systems and organs. Questions remain as to how hCMV carriage affects the human host. We used anti-CMV antibody titers as a stratifying criterion to examine the impact of "intensity" of hCMV infection as a potential biomarker of aging, inflammation, and immune homeostasis in a cohort of 247 participants stratified into younger (21-40 years) and older (> 65 years of age) groups. We showed that anti-CMV antibody titers increased with age and directly correlated to increased levels of soluble tumor necrosis factor (sTNFR) I in younger but not older participants. CD8 + cell numbers were reduced in the older group due to the loss in CD8 + T naïve (Tn) cells. In CMV carriers and, in particular, in anti-CMV Ab-high participants, this loss was mitigated or reversed by an increase in the numbers of CD8 + T effector memory (Tem) and T effector memory reexpressing CD45RA (Temra) cells. Analysis of CD38, HLA-DR, and CD57 expression revealed subset (CD4 or CD8)-specific changes that correlated with anti-CMV Ab levels. In addition, anti-CMV Ab levels predicted anti-CMV CD8 T cell responsiveness to different CMV open reading frames (ORFs) selectively in older participants, which correlated to the transcriptional order of expression of specific CMV ORFs. Implications of these results for the potential predictive value of anti-CMV Ab titers during aging are discussed.

Indexed as

AgingAntibodies, ViralCytomegalovirusCytomegalovirus InfectionsAdultAgedBiomarkersCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedYoung AdultAntibodies, ViralBiomarkersCMVImmune agingImmune profiles

Identifiers

PMID38512581
PMCPMC11336022
OpenAlexW4393039785

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.